Article thumbnail
Location of Repository

Essential Role of Cdc42 in Ras-Induced Transformation Revealed by Gene Targeting

By Kristy R. Stengel and Yi Zheng

Abstract

The ras proto-oncogene is one of the most frequently mutated genes in human cancer. However, given the prevalence of activating mutations in Ras and its association with aggressive forms of cancer, attempts to therapeutically target aberrant Ras signaling have been largely disappointing. This lack of progress highlights the deficiency in our understanding of cellular pathways required for Ras-mediated tumorigenesis and suggests the importance of identifying new molecular pathways associated with Ras-driven malignancies. Cdc42 is a Ras-related small GTPase that is known to play roles in oncogenic processes such as cell growth, survival, invasion, and migration. A pan-dominant negative mutant overexpression approach to suppress Cdc42 and related pathways has previously shown a requirement for Cdc42 in Ras-induced anchorage-independent cell growth, however the lack of specificity of such approaches make it difficult to determine if effects are directly related to changes in Cdc42 activity or other Rho family members. Therefore, in order to directly and unambiguously address the role of Cdc42 in Ras-mediated transformation, tumor formation and maintenance, we have developed a model of conditional cdc42 gene in Ras-transformed cells. Loss of Cdc42 drastically alters the cell morphology and inhibits proliferation, cell cycle progression and tumorigenicity of Ras-transformed cells, while non-transformed cells or c-Myc transformed cells are largely unaffected. The loss of Cdc42 in Ras-transformed cells results in reduced Akt signaling, restoration of which could partially rescues the proliferation defects associated with Cdc42 loss. Moreover, disruption of Cdc42 function in established tumors inhibited continued tumor growth. These studies implicate Cdc42 in Ras-driven tumor growth and suggest that targeting Cdc42 is beneficial in Ras-mediated malignancies

Topics: Research Article
Publisher: Public Library of Science
OAI identifier: oai:pubmedcentral.nih.gov:3377703
Provided by: PubMed Central

Suggested articles

Citations

  1. (1995). A
  2. (1987). A cytoplasmic protein stimulates normal N-ras p21 GTPase, but does not affect oncogenic mutants.
  3. (2009). A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene.
  4. (1997). A novel Cdc42Hs mutant induces cellular transformation.
  5. (1995). Absence of p53 allows direct immortalization of hematopoietic cells by the myc and raf oncogenes.
  6. (2009). Actin machinery and mechanosensitivity in invadopodia, podosomes and focal adhesions.
  7. (2003). Activated Cdc42 sequesters c-Cbl and prevents EGF receptor degradation.
  8. (1994). Activation of phosphoinositide 3-kinase activity by Cdc42Hs binding to p85.
  9. (2006). AKT can be activated in the nucleus.
  10. (2006). BRAF mutation predicts sensitivity to MEK inhibition.
  11. (2011). Cancer therapy based on oncogene addiction.
  12. (2006). Cdc42 deficiency causes Sonic hedgehog-independent holoprosencephaly.
  13. (2011). Cdc42 in oncogenic transformation, invasion, and tumorigenesis.
  14. (2008). Cdc42 is highly expressed in colorectal adenocarcinoma and downregulates ID4 through an epigenetic mechanism.
  15. (2004). Cdc42: new roads to travel.
  16. (2011). Compartmentalized Ras proteins transform NIH 3T3 cells with different efficiencies.
  17. (2009). FAK phosphorylation by ERK primes ras-induced tyrosine dephosphorylation of FAK mediated by PIN1 and PTP-PEST.
  18. (2001). Function of the Rho family GTPases in Rasstimulated Raf activation.
  19. (2006). Gene targeting of Cdc42 and Cdc42GAP affirms the critical involvement of Cdc42 in filopodia induction, directed migration, and proliferation in primary mouse embryonic fibroblasts.
  20. (2001). Hall A
  21. Hall A (2003) Cdc42 regulates GSK-3beta and adenomatous polyposis coli to control cell polarity.
  22. (2007). Hyperactive Ras in developmental disorders and cancer.
  23. (2007). progression and prognosis of cutaneous melanoma.
  24. (2010). Rac1 and Cdc42 are regulators of HRasV12-transformation and angiogenic factors in human fibroblasts.
  25. (2010). Rac1 targeting suppresses p53 deficiency-mediated lymphomagenesis.
  26. (2010). Ras history: The saga continues.
  27. (2002). Ras signalling on the endoplasmic reticulum and the Golgi.
  28. (2008). RAS: target for cancer therapy.
  29. (2009). Ras/MAPK signaling from endomembranes.
  30. (2007). Rho GTPase Cdc42 coordinates hematopoietic stem cell quiescence and niche interaction in the bone marrow.
  31. (1999). Rho GTPases are over-expressed in human tumors.
  32. (2002). Rho GTPases in human breast tumours: expression and mutation analyses and correlation with clinical parameters.
  33. (2005). Role of group A p21-activated kinases in activation of extracellular-regulated kinase by growth factors.
  34. (1995). Selective activation of the JNK signaling cascade and c-Jun transcriptional activity by the small GTPases Rac and Cdc42Hs.
  35. (2011). Signaling role of Cdc42 in regulating mammalian physiology.
  36. (2009). Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells.
  37. (2009). Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1.
  38. (2000). The cell-polarity protein
  39. (1998). The protein kinase Pak3 positively regulates Raf-1 activity through phosphorylation of serine 338.
  40. (1999). Tools of the trade: use of dominant-inhibitory mutants of Rasfamily GTPases.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.